NC-based Areteia Therapeutics secures additional $75million in series A round funding. The round received backing from Marshall Wace and Viking Global Investors, bringing the total sum to $425M.

whom Bain Capital Life Sciences led the initial investment syndicate that also included Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Maverick Capital, Sanofi, and Population Health Partners.

Read also – IL-based Ascent Technologies Acquired Waymark

The money will be used by the business to assist the extension of the ongoing Phase III dexpramipexole development program for eosinophilic asthma.

Areteia Therapeutics is a clinical stage biotechnology business led by CEO and President Jorge Bartolome. Its mission is to discover and offer innovative immunology and inflammation medications that enable respiratory patients to regain control over their disease and their lives.

Read also – FL-based Odyssey Secures $6Million in Funding

Dexpramipexole, the company’s principal medication candidate, is an oral eosinophil maturation inhibitor that, if authorized, reduces blood and tissue eosinophil counts to target eosinophilic inflammation.

About Areteia Therapeutics

Areteia Therapeutics is a new biotechnology business whose goal is to develop the first possible oral treatment for eosinophilic asthma, enabling patients to take back control of their life and better manage their illness.

Read also – NYC-based Tandym Group Acquired Kolter Solutions